Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-center Study to Evaluate the Hemodynamic Effects of Riociguat (BAY 63-2521) as Well as Safety and Kinetics in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms LEPHT
- Sponsors Bayer; Bayer HealthCare
- 14 Jul 2019 Trial has been completed in Spain, according to European Clinical Trials Database record.
- 19 Mar 2019 This trial has been completed in Austria, according to European Clinical Trials Database.
- 24 Jan 2019 Planned End Date changed from 30 Apr 2020 to 30 Apr 2021.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History